Research programme: long-acting hepatitis B therapeutics - Gilead Sciences/DURECT Coporation
Latest Information Update: 28 Aug 2023
At a glance
- Originator DURECT Corporation
- Developer DURECT Corporation; Gilead Sciences
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for research development in Hepatitis-B in USA (Injection, Controlled release)
- 22 Jul 2019 Gilead Sciences enters into an option agreement with DURECT Corporation for SABER-based products for Hepatitis B
- 22 Jul 2019 Early research in Hepatitis B in USA (Injection)